IMMUNOGENICITY AND SAFETY STUDY OF GLAXOSMITHKLINE BIOLOGICALS' HUMAN PAPILLOMAVIRUS (HPV) VACCINE (GSK-580299) AND MERCK'S GARDASIL® VACCINE WHEN ADMINISTERED ACCORDING TO ALTERNATIVE 2-DOSE SCHEDULES IN 9-14 YEAR OLD FEMALES: